Skip to main content

PTC Receives Prestigious Gallup Honor

April 7, 2021
  1. PTC Receives Prestigious Gallup Honor

    PTC is excited to announce our company has been named a winner of the 2021 ”Don Clifton Strengths-Based Culture Award” from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of their employees. This honor is named for Don Clifton, an educational psychology professor at the University of Nebraska-Lincoln and…

  2. Phase 2/3 Clinical Trial to Evaluate Potential COVID-19 Treatment

    The U.S. Food and Drug Administration has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19. PTC299 is an oral investigational drug with a novel dual-mechanism of action that has the potential to address the two critical elements of COVID-19: High viral…

  3. Expanding Areas of Therapeutic Focus – Phenylketonuria (PKU)

    PTC has successfully completed acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic rare diseases, including phenylketonuria (PKU) and other rare diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. “This acquisition adds a well-established late-stage PKU clinical…

  4. Expanding Gene Therapy Development in a State-of-the-Art Biologics Facility

    A long-term lease agreement with Bristol-Myers Squibb Company provides us more than 185,000 square feet of space, including an existing state-of-the-art biologics production facility and supporting research and operations buildings on the BMS Hopewell, New Jersey campus. We plan to further develop the biologics facility to support gene therapy production and foster innovation and employment…